Mankind Pharma Ltd (MANKIND) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 543904 | NSE: MANKIND | Pharmaceuticals & Drugs | Mid Cap

Mankind Pharma Share Price

2,200 -8.35 -0.38%
as on 05-Dec'25 09:52

Mankind Pharma Ltd (MANKIND) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 543904 | NSE: MANKIND | Pharmaceuticals & Drugs | Mid Cap

DeciZen - make an informed investing decision on Mankind Pharma

Based on:

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Mankind Pharma stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
54.57
Market Cap:
91,161.8 Cr.
52-wk low:
2,115.5
52-wk high:
3,050

Is Mankind Pharma Ltd an attractive stock to invest in?

1. Is Mankind Pharma Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Mankind Pharma Ltd is a good quality company.

2. Is Mankind Pharma Ltd undervalued or overvalued?

The key valuation ratios of Mankind Pharma Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Mankind Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Mankind Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Mankind Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Mankind Pharma Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 33.7%32.7%31.8%22.1%37%34.2%31.8%21.2%25.2%17.1%-
Value Creation
Index
2.01.91.81.02.32.01.80.51.20.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3,1503,4953,9183,8294,7945,5237,4868,1278,6299,4989,673
Sales YoY Gr.-11%12.1%-2.3%25.2%15.2%35.5%8.6%6.2%10.1%-
Adj EPS 1112.216.312.323.526.934.430.944.142.840.5
YoY Gr.-11.2%33.4%-24.3%90.3%14.8%27.9%-10.3%42.8%-2.9%-
BVPS (₹) 52.565.974.876.591.2118.2163.3194.3241.6353.8375.7
Adj Net
Profit
4394896524949401,0781,3791,2371,7671,7671,671
Cash Flow from Ops. 4825075405379609838211,7991,7362,322-
Debt/CF from Ops. 000.70.400.10.8003-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 13.1%14.7%8.3%10.1%
Adj EPS 16.3%12.8%7.6%-2.9%
BVPS23.6%31.2%29.4%46.4%
Share Price - - - -16%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
21.620.623.116.32825.724.517.320.214.511.1
Op. Profit
Mgn %
20.520.219.918.42624.924.620.926.32726.7
Net Profit
Mgn %
141416.612.919.619.518.415.220.518.617.3
Debt to
Equity
000.10.1000.1000.50.2
Working Cap
Days
1321311181079210411211711311698
Cash Conv.
Cycle
171595719171228407

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 11.10%

Sales growth has been subdued in last 3 years 8.26%

Net Profit has been subdued in last 3 years 7.56%

Sales growth is not so good in last 4 quarters at 5.57%

Latest Financials - Mankind Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 40.5 42.4
TTM Sales (₹ Cr.) 9,673 13,577
BVPS (₹.) 375.7 370.3
Reserves (₹ Cr.) 15,469 15,245
P/BV 5.88 5.96
PE 54.57 52.07
From the Market
52 Week Low / High (₹) 2115.50 / 3050.00
All Time Low / High (₹) 1240.75 / 3050.00
Market Cap (₹ Cr.) 91,162
Equity (₹ Cr.) 41.3
Face Value (₹) 1
Industry PE 40.7

Management X-Ray of Mankind Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Mankind Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Mankind Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales3,1503,4953,9183,8294,7945,5237,4868,1278,6299,498
Operating Expenses 2,5042,7933,1393,1243,5504,1515,6486,4296,3626,935
Manufacturing Costs5374103106147178198192249274
Material Costs1,1991,2961,4311,3921,5731,7822,5212,8452,5702,597
Employee Cost 5736637987859911,1671,4631,7011,9212,132
Other Costs 6797618088418391,0231,4661,6911,6221,933
Operating Profit 6457017797051,2441,3721,8381,6982,2672,563
Operating Profit Margin (%) 20.5%20.1%19.9%18.4%25.9%24.8%24.6%20.9%26.3%27.0%
Other Income 76892016494155204163271493
Interest 221940118482817372
Depreciation 381628386278123270335378
Exceptional Items 0000000000
Profit Before Tax 6817729336911,2651,4401,8711,5632,1852,306
Tax 207240247177307356482315413422
Profit After Tax 4755326865149581,0841,3891,2481,7731,884
PAT Margin (%) 15.1%15.2%17.5%13.4%20.0%19.6%18.6%15.4%20.5%19.8%
Adjusted EPS (₹)11.913.317.112.823.927.134.731.244.345.7
Dividend Payout Ratio (%)63%0%25%35%13%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 2,1022,6392,9973,0653,6514,7346,5407,7849,68014,597
Share Capital 20204040404040404041
Reserves 2,0822,6192,9573,0253,6114,6946,5007,7449,63914,555
Minority Interest0000000000
Debt003601900956840157,066
Long Term Debt0000000004,943
Short Term Debt003601900956840152,123
Trade Payables326368452387487594921802525564
Others Liabilities 991652002093714447937851,2971,602
Total Liabilities 2,5283,1724,0093,8514,5105,8678,9399,37111,51623,828

Fixed Assets

Gross Block2795336018831,1111,2223,2873,7704,5734,845
Accumulated Depreciation3651781161722403666331,0261,375
Net Fixed Assets 2434815237689399822,9213,1373,5463,471
CWIP 70141322211148166387495209207
Investments 7689861,4021,6981,7842,3972,5263,1024,21516,683
Inventories4105224694825338271,2671,0321,1261,091
Trade Receivables157137243139419369471493769895
Cash Equivalents 69928172198477139155484306
Others Assets 8108129704814896501,2299571,1661,175
Total Assets 2,5283,1724,0093,8514,5105,8678,9399,37111,51623,828

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 4825075405379609838211,7991,7362,322
PBT 6817729336911,2651,4401,8711,5632,3262,390
Adjustment -6-8-703213797-4227165339
Changes in Working Capital 13-29-7359-168-156-586294-33364
Tax Paid -206-226-250-246-274-397-460-285-421-471
Cash Flow From Investing Activity -103-513-516-306-396-1,127-1,360-1,041-1,665-12,115
Capex -64-280-231-165-164-192-2,181-580-280-346
Net Investments 108-3218588-165-958680-506-1,4431,506
Others -146-202-471-229-67231414558-13,275
Cash Flow From Financing Activity -363-18-240-55989579-710-59,845
Net Proceeds from Shares 0000000002,963
Net Proceeds from Borrowing 0000000005,000
Interest Paid -1-1-16-41-4-5-7-26-8-349
Dividend Paid -3000-300-24-30200000
Others -61-0324-175-25394586-68432,231
Net Cash Flow 17-831-95-5540486653

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)23.3822.4324.3516.9628.5325.8624.6517.4320.315.52
ROCE (%)33.6532.6531.7522.1136.9534.1631.8421.225.1617.05
Asset Turnover Ratio1.311.231.091.011.191.11.050.930.860.55
PAT to CFO Conversion(x)1.010.950.791.0410.910.591.440.981.23
Working Capital Days
Receivable Days19151818202520212631
Inventory Days47484644374349504441
Payable Days93981051101011111101119477

Mankind Pharma Ltd Stock News

Mankind Pharma Ltd FAQs

The current trading price of Mankind Pharma on 05-Dec-2025 09:52 is ₹2,200.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Mankind Pharma stood at ₹91,161.8.
The latest P/E ratio of Mankind Pharma as of 04-Dec-2025 is 54.57.
The latest P/B ratio of Mankind Pharma as of 04-Dec-2025 is 5.88.
The 52-week high of Mankind Pharma is ₹3,050 and the 52-week low is ₹2,115.5.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Mankind Pharma is ₹9,673 ( Cr.) .

About Mankind Pharma Ltd

Mankind Pharma was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name ‘Mankind Pharma Private Limited’, pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi (RoC). Pursuant to the conversion of the company to a public limited company and as approved by its shareholders pursuant to a special resolution dated July 14, 2005 the name of the company was changed to ‘Mankind Pharma Limited’ and the RoC issued a fresh certificate of incorporation on April 13, 2006. 

It is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices, and has an established track record of building and scaling brands in-house.

It is present in several acute and chronic therapeutic areas in India, including anti- infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals /nutrients and respiratory. It entered the consumer healthcare industry in 2007 and has since established several differentiated brands in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories. 

Business area of the company

The company is India’s one of the leading pharmaceutical company with a diversified portfolio - from pharma and super specialty to consumer healthcare backed by strong in-house R&D capabilities with an established and deeply penetrated presence across India. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

Therapeutic Areas

  • Anti-infectives
  • Cardiovascular
  • Gastrointestinal
  • Vitamins/minerals/nutrients
  • Respiratory
  • Anti-diabetic
  • Dermatology
  • Gynaecology
  • Pain/analgesics
  • Neuro/CNS

Awards, accreditations or recognition

  • 2007: Emerging Company of the year award at the Pharma Excellence Awards 2007.
  • 2011: Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.
  • 2017: Award for Best Design in Healthcare at Healthcare Leadership Awards 2017.
  • 2018: Best Condom Brand of the Year award at Sex Brand Awards.
  • 2018: Pharma OTC company of the year award at Pharma Excellence Awards 2018.
  • 2021: Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for manufacturing.
  • 2021: Silver Award for Good Health Brand at IHW Awards 2021.
  • 2022: E4m Pride of India - The Best of Bharat Awards 2022 by exchange4media.
  • 2022: Award for Branding and Marketing Excellence for the Strategic Initiative to Introduce DMF Quality Drugs in India at National Awards for Leadership & Excellence 2022.
  • 2022: EHS Best Practices award at Greentech International EHS Award 2023.
  • 2022: Docflix won the Digital Jalebi (DJ Interactive Solutions) award at the Maddies 2022.
  • 2022: Best Energy Efficient Case Study (SME Category) at CII National Energy Efficiency Circle Competition by Confederation of Indian Industry.
  • 2022: Short film, she can carry both by Prega News won 1st prize at Council for Fair Business Practices Consumer Film Festival.
  • 2023: e4m Pride of India Brands- The Best of Bharat Awards.
  • 2023: e4m Pride of India Brands- The Best of North Award.
  • 2023: NavBharat Environment Conclave- Most Innovative Green Healthcare Company.
  • 2023: Healthcare Innovation Excellence Award- Innovative Marketing Campaign of the Year - Shakti Awareness Program (PregaNews).
  • 2024: ET Awards- Entrepreneur of the Year Award.
  • 2024: The Indian Brand and Leadership Conclave- Most Trusted Brand of the Nation – PregaNews.

History and milestones

  • 2004: Entered the chronic pharmaceutical segment with the launch of ‘Amlokind’ tablets and ‘Glimestar’ tablets amongst others.
  • 2005: Set up its first manufacturing facility at Paonta Sahib, Himachal Pradesh.
  • 2005: Entered the ophthalmic pharmaceutical segment with the launch of ‘Lubistar Eye Drops’ and ‘Tobastar Eye Drops’ amongst others.
  • 2007: Entered the consumer healthcare segment with the launch of ‘Manforce’ brand. 2007: Entered the animal healthcare segment with launch of ‘Bandykind’ and ‘Ceftiforce’ amongst others.
  • 2007: Raised Rs 72 crore from Monet Limited.
  • 2009: Set up its manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh.
  • 2010: Launched ‘Preganews’ brand in the consumer healthcare segment.
  • 2012: Setup its first R&D centre at IMT Manesar, Haryana.
  • 2014: Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan).
  • 2014: Set up its manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh
  • 2015: Incorporated its Subsidiary, Lifestar Pharma LLC in the US.
  • 2015: Incorporated its Subsidiary, Mankind Pharma Pte. Limited in Singapore.
  • 2017: Set up its manufacturing facility in Sikkim.
  • 2018: Its manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time.
  • 2019: Entered the female infertility segment with the launch of ‘Dydroboon’ tablets.
  • 2020: Incorporated its Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal.
  • 2020: Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of ‘Cilaheart’ tablets and ‘Statpure’ tablets.
  • 2020: Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of ‘Zukanorm’ tablets.
  • 2021: Incorporated its Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE.
  • 2021: Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of ‘Mlife’ tablets.
  • 2021: Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of ‘Trugaba-NT’ tablets and ‘Prebris-MNT’ tablets.
  • 2022: Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited.
  • 2022: Entered into transplant segment with the launch of ‘Pangraf Capsules’ and ‘Mycept’ tablets amongst others.
  • 2022: Entered into oncology segment with the launch of ‘Pacliall’ injection amongst others.
  • 2022: Acquired the brands ‘Daffy’ and ‘Combihale’ from Dr. Reddy’s Laboratories.
  • 2023: Successfully listed on NSE and BSE.
  • 2023: Launch of International Quality API products in India.
  • 2023: Commercialised India’s First fully integrated facility for Dydrogesterone at Udaipur.
  • 2024: Acquired 100% stake in BSV Limited.
  • 2024: Entered into in-licensing agreements with: 1. Astra Zeneca - Symbicort 2. Second product from Novartis - Crenzlo (Inclisiran) 3. Takeda – Vonoprazan.
  • 2024: Partnered with Innovent Biologics to commercialise Sintilimab in India.
  • 2025: Mankind Pharma collaborates with OpenAI to drive AI-Enabled transformation across Pharma Value Chain.
  • 2025: Mankind Pharma Gets CDSCO Nod to Begin Phase 1 Trials of Novel Autoimmune Drug Candidate MKP11093.
  • 2025: Mankind Unveils HealthOK’s 100% Vegetarian Multivitamin tablets Campaign with Archana Puran Singh.
You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×